Supply Chain Operations for Medicines and Devices

Establish and maintain a seamless supply of commercial and investigational products in Europe

Combining long-term experience in implementing and managing corporate supply chains, Veristat can provide full support in supply chain operations, from Market Entry in the EU and Switzerland to Identification & Authentication, and Distribution of your commercial or investigational drug and device products. Our Supply Chain experts offer Interim Management support for tailored solutions that meet your requirements.

Together with our experienced Quality Assurance team, we perform systematic gap assessments of Quality Management Systems, and identify the impacts of regulatory or internal changes and any areas requiring action. With extensive experience in GxP Audits, Serialization and Traceability, Master Data Management and Early Access Schemes, SFL offers solutions to address your business needs and maintain continuity of your product supply.

It's never too early to start.   Let's Talk. 

Supply Chain Management Across the Clinical Development and Commercialization Lifecycle

Market Entry in EU/CH

  • - Distribution models
  • - Stakeholders' roles
  • - GxP licensure requirements
  • - Setting up supply chain
supply chain market entry in Europe

Identification & Authentication

  • - UDI system for devices
  • - Sterilization of medicinal products
  • - Master data
  • - Product marking
supply chain identification and authentication in Europe

Interim Management

  • - Distribution projects
  • - Process (re-)engineering
  • - Master data managemenet
  • - Managing changes
interim supply chain management


  • - Early access schemes
  • - GDP risk management
  • - Service provider selection
  • - 3PL audit
investigational product supply chain distribution, commercial product distribution

Need to ensure a seamless supply of your investigational and commercial products? 


Learn More with These Resources

Fact Sheet

Rare Disease Fact Sheet


Regulatory Guidance Monthly Review - February 2024


Regulatory Guidance Monthly Review - January 2024